Somanetics
This article was originally published in The Gray Sheet
Executive Summary
Will submit a new 510(k) for its INVOS 3100 cerebral oximeter; the firm cites "timing and costs" as reasons for reversing plans to appeal FDA's Nov. 12 rescission of the device's 510(k) ("The Gray Sheet" Dec. 6, I&W-1). The company says the new filing is "the most efficient and timely way to satisfy the FDA and resume domestic sales of its product." Somanetics says the new 510(k) will address agency concerns with data integrity in the original 510(k). The company also reports that it is taking measures to reduce its current operating costs "by approximately 40%" and is extending the redemption date of its Class B warrants to May 4, 1995
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.